Five Year Outcome of Lentiviral Gene Therapy for Human Beta-Thalassemia, Lessons and Prospects

Philippe Leboulch

doi:10.4081/thal.2013.s1.e43

You are currently viewing a new version of our website. To view the old version click .

Thalassemia Reports is published by MDPI from Volume 12 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.

Brief Report

26 March 2013

Five Year Outcome of Lentiviral Gene Therapy for Human Beta-Thalassemia, Lessons and Prospects

Institute of Emerging Diseases and Innovative Therapies, INSERM U. 962, Brigham and Women’s Hospital, France and Harvard Medical School, University Paris 11 Bluebird Bio, Boston, MA 02115, USA

Thalass. Rep.2013, 3(s1), e43;https://doi.org/10.4081/thal.2013.s1.e43

Version Notes

Order Reprints

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

This article is distributed under the terms of the Creative Commons [...]

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

Bone Marrow Transplantation for Thalassemia: A Global Perspective

ENERCA—European Network for Rae and Congenital Anaemias 2002–2012. 10 Years of Life